Variance of spinal osteoporosis induced by dexamethasone and methylprednisolone and its associated mechanism

Ren, Hui; Liang, De; Tang, Jingjing; Cui, Jianchao; Wei, Qiushi; Zhang, Shuncong; Yao, Zhensong; Shen, Gengyang; Lin, Sheng‐Xiang

doi:10.1016/j.steroids.2015.07.006

Cited by 34 publications

(30 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The laboratory rat was used as a model in this study because it is convenient, easy and safe to handle, costeffective and is the most frequently used animal model for glucocorticoids induced osteoporosis followed by mice (29)(30)(31). Dexamethasone was used to induce osteoporosis as it was reported to be the most potent inductor of osteoporosis, among other corticosteroids, in animal models; moreover, it is characterized by its long-term action thus avoiding the need for daily injections (20,31). The dosage and interval used to induce systemic osteoporosis was documented to induced generalized osteoporosis (20,32).…”

Section: Discussionmentioning

confidence: 99%

“…Dexamethasone was used to induce osteoporosis as it was reported to be the most potent inductor of osteoporosis, among other corticosteroids, in animal models; moreover, it is characterized by its long-term action thus avoiding the need for daily injections (20,31). The dosage and interval used to induce systemic osteoporosis was documented to induced generalized osteoporosis (20,32).…”

Section: Discussionmentioning

confidence: 99%

“…Rats were given Dexamethasone (Amriya for pharmaceutical industries, Alexandria -Egypt) (0.6mg/kg twice/week by subcutaneous injection) for 12 weeks, to induce osteoporosis (20).…”

Section: •Group Ii: Glucocorticoids Group (Gcs)mentioning

confidence: 99%

See 2 more Smart Citations

Effect of Bisphosphonates on the Alveolar Bone of Rats With Glucocorticoids Induced Osteoporosis

Sherif

Masry

Kawana

et al. 2019

Alexandria Dental Journal

View full text Add to dashboard Cite

INTRODUCTION: Bone is a unique tissue that undergoes frequent remodeling. An imbalance between bone formation and resorption results in osteoporosis. Glucocorticoids (GCs) are widely used clinically as anti-inflammatory and immunomodulatory. However, their prolonged use may induce osteoporosis. Currently, evidences revealed that also the alveolar processes are subject to osteoporosis. Bisphosphonates, such as Alendronate, Risedronate and Zoledronate, are recommended by several international guidelines as the first-line therapy for the prevention and treatment of generalized glucocorticoids induced osteoporosis (GIOP). OBJECTIVES: To evaluate the effect of bisphosphonates (Risedronate) on the alveolar bone of rats with glucocorticoids induced osteoporosis. MATERIALS AND METHODS: Thirty female albino rats were divided into 3 equal groups (10 rats each) as follows: Group I: control group. Group II: glucocorticoids group (Dexamethasone 0.6mg/kg twice/week subcutaneously). Group III: Risedronate treated group; rats were given Dexamethasone (0.6mg/kg twice/week subcutaneously) and Risedronate (1mg/kg/day orally). After 12 weeks, rats were euthanized, and the mandibular alveolar bone was evaluated histologically by light microscope and ultra-structurally by scanning electron microscopy and energy dispersive X-ray (EDX) microanalysis. RESULTS: Group II showed deterioration of the alveolar bone in comparison to the control group I. The alveolar bone structure in Group III rats, treated by bisphosphonates (Risedronate), showed remarkable improvement both histologically and ultrastructurally in comparison to group II. Moreover, EDX analysis revealed a significant decrease of calcium levels in group II in comparison to group I. However, in group III calcium levels were restored to normal levels comparable to the control group I. CONCLUSIONS: Glucocorticoids intake induces loss of the alveolar bone; which, could be counterbalanced by bisphosphonates.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Bisphosphonates on the Alveolar Bone of Rats With Glucocorticoids Induced Osteoporosis

Sherif

Masry

Kawana

et al. 2019

Alexandria Dental Journal

View full text Add to dashboard Cite

show abstract

“…We record 1-9 points from low to high according to spinal deformation degree, respectively. We record 1 point or 0 point respectively according to have or no features as follows: (1) have or no bone trabecula of transverse vertebral levels disappearing, (2) have or no vertical longitudinal bone trabecular compensatory enlargement, (3) have or no bone cortex of vertebral body thinning, (4) have or no vertebral fracture, (5) have or no back/ whole body pain, (6) have or no smoking history, (7) have or no glucocorticoids (GCs) application history [31], (8) have or no drinking history, (9) have or no history of fracture before 50-yearold. Finally, we need to get the average from each item.…”

Section: Experimental Materials and Methodsmentioning

confidence: 99%

Application of artificial neural network in the diagnostic system of osteoporosis

Xiang

2016

Neurocomputing

View full text Add to dashboard Cite

“…after short-and long-time treatment with glucocorticoids in mice and rats [Yao et al, 2008;Ren et al, 2015a], but also in male humans after 96-hour treatment with dexamethasone [Brabnikova Maresova et al, 2013]. They discussed apoptotic effects of dexamethasone on osteocytes as a possible reason.…”

Section: Discussionmentioning

confidence: 99%

Rat Osteosarcoma Cells as a Therapeutic Target Model for Osteoregeneration via Sclerostin Knockdown

Sedaghati

Jahroomishirazi²,

Starke

et al. 2016

Cells Tissues Organs

View full text Add to dashboard Cite

There are various conceptually different strategies to improve bone regeneration and to treat osteoporosis, each with distinct inherent advantages and disadvantages. The use of RNA interference strategies to suppress the biological action of catabolic factors or antagonists of osteogenic proteins is promising, and such strategies can be applied locally. They are comparably inexpensive and do not suffer from stability problems as protein-based approaches. In this study, we focus on sclerostin, encoded by the SOST gene, a key regulator of bone formation and remodeling. Sclerostin is expressed by mature osteocytes but also by late osteogenically differentiated cells. Thus, it is difficult and requires long-term cultures to investigate the effects of SOST silencing on the expression of osteogenic markers using primary cells. We, therefore, selected a rat osteosarcoma cell line, UMR-106, that has been shown to express SOST and secrete sclerostin in a comparable fashion as late osteoblasts and osteocytes. We investigated the effects of differentiating supplements on SOST expression and sclerostin secretion in UMR-106 cells and found that addition of 100 ng/ml of bone morphogenetic protein (BMP)-2 strongly induced sclerostin secretion, whereas dexamethasone inhibited secretion. Effects of silencing SOST in UMR-106 cells cultured in various differentiation media including BMP-2 and/or dexamethasone were determined next with the aim to find promising test conditions for a readout system for the evaluation of future small interfering RNA release formulations for local induction of bone formation. We found a direct correlation between attenuated SOST expression and an increase in the osteogenic potential of UMR-106 cells. The combination of SOST silencing and BMP-2 could synergistically improve osteogenic factors. A lowered proliferation rate in silenced groups may indicate a faster switch to differentiation.

show abstract

Variance of spinal osteoporosis induced by dexamethasone and methylprednisolone and its associated mechanism

Cited by 34 publications

References 51 publications

Effect of Bisphosphonates on the Alveolar Bone of Rats With Glucocorticoids Induced Osteoporosis

Effect of Bisphosphonates on the Alveolar Bone of Rats With Glucocorticoids Induced Osteoporosis

Application of artificial neural network in the diagnostic system of osteoporosis

Rat Osteosarcoma Cells as a Therapeutic Target Model for Osteoregeneration via Sclerostin Knockdown

Contact Info

Product

Resources

About